

The Board of Pharmacy has received notice of the following product withdrawal. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Immune Globulin Subcutaneous (Human)

Hizentra® 20% (10g/50 mL)

Lot Number: P100343632

NDC Number: 44206-0455-10

CSL Behring has instituted a withdrawal of one (1) lot of HIZENTRA at the PATIENT level due to an increased frequency of reports of injection-site reactions and hypersensitivity-type of events after administration. Injection-site reactions and hypersensitivity are known risks with subcutaneous Immune Globulin products. The impacted lot of HIZENTRA was shipped from CSL Behring beginning on October 5, 2021.